Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mgb-BP-3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Design and endpoints of two prospective Phase 3 studies were approved by the US FDA. The Phase 3 studies will include superiority of MGB-BP-3 against vancomycin in the critical measure of sustained clinical response as one of their endpoints.
Product Name : Mgb-BP-3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2021
Lead Product(s) : Mgb-BP-3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mgb-BP-3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3
Details : The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI.
Product Name : Mgb-BP-3
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2020
Lead Product(s) : Mgb-BP-3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
